---
title: "Methylation-based ctDNA (Guardant360) for Surveillance of Non‑Viral Head and Neck Cancer"
id: "medrxiv-3-methylation-based-ctdna-for-post-treatment-surveillance-of-non-viral-head-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-methylation-based-ctdna-for-post-treatment-surveillance-of-non-viral-head-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1?rss=1"
published_at: "2026-09-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Methylation-based ctDNA (Guardant360) for Surveillance of Non‑Viral Head and Neck Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-methylation-based-ctdna-for-post-treatment-surveillance-of-non-viral-head-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1?rss=1)
- **Published At:** 2026-09-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This single‑institution retrospective cohort evaluated a **methylation‑based ctDNA** assay (Guardant360) for post‑treatment surveillance in non‑virally associated head and neck squamous cell carcinoma (**HNSCC**). - Inclusion: 50 patients with non‑metastatic, non‑viral HNSCC who completed definitive therapy and had ≥1 Guardant360 plasma test between January 2024 and October 2025. - Guardant360 detects tumor‑specific DNA methylation patterns in plasma cell‑free DNA; a positive test threshold was a methylation signal ≥0.05%. - Patient characteristics: most primaries in the larynx (38%) or oral cavity (36%); 72% had AJCC stage IVA–IVB; 69% had T3–T4 tumors; 48% had N2–N3 disease. - Treatments received were chemoradiation (54%) or surgery (46%). Median follow‑up was 18.0 months. - Outcomes: 13 patients experienced recurrence; 12 patients had positive ctDNA results during surveillance. - Diagnostic performance: sensitivity 76.9%, specificity 94.6%, positive predictive value (PPV) 83.3%, negative predictive value (NPV) 92.1%, and AUC 0.858 (95% CI 0.733–0.982). - A positive ctDNA result was reported to associate with worse progression‑free survival (reported 1‑year PFS 25.0% vs 96.4% for positive vs negative), but the p‑value and full survival data reporting in the source were truncated and not fully provided. - The study is a preprint and has not undergone peer review; authorship and institutional affiliations are reported, and correspondence contact is listed, but further methodological and longitudinal details beyond the abstract were not reported in the provided source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=WsV3kCg4TAuIGdR3LB4xAW_U6cljlXFQ.4NUXI09mxs-1789953731.673986-1.2.1.1-Yo1qXHiyrlfi9lZrZKynPQLvo7yzSujTKsSGecP3zw2XWzM5qPXfuTRwICSY0P6c) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer Danielle Tomer, Patrik Brodin, Nikhil Malik, Sadiya Mayat, Christian Velten, Byung-Han Rhieu, Enrico Castellucci, Bradley Schiff, Vikas Mehta, Richard Smith, Shalom Kalnicki, Madhur Garg, Rafi Kabarriti doi: https://doi.org/10.64898/2026.09.17.26363361 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Danielle Tomer 1 Albert Einstein College of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Danielle%2BTomer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tomer%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADanielle%2BTomer%2B) Patrik Brodin 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patrik%2BBrodin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brodin%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatrik%2BBrodin%2B) Nikhil Malik 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nikhil%2BMalik%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Malik%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANikhil%2BMalik%2B) Sadiya Mayat 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sadiya%2BMayat%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mayat%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASadiya%2BMayat%2B) Christian Velten 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christian%2BVelten%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Velten%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristian%2BVelten%2B) Byung-Han Rhieu 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Byung-Han%2BRhieu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rhieu%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AByung-Han%2BRhieu%2B) Enrico Castellucci 3 Department of Medical Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Enrico%2BCastellucci%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Castellucci%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEnrico%2BCastellucci%2B) Bradley Schiff 4 Department of Otorhinolaryngology - Head & Neck Surgery, Montefiore Einstein Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bradley%2BSchiff%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schiff%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABradley%2BSchiff%2B) Vikas Mehta 4 Department of Otorhinolaryngology - Head & Neck Surgery, Montefiore Einstein Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vikas%2BMehta%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mehta%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVikas%2BMehta%2B) Richard Smith 4 Department of Otorhinolaryngology - Head & Neck Surgery, Montefiore Einstein Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2BSmith%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Smith%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichard%2BSmith%2B) Shalom Kalnicki 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shalom%2BKalnicki%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kalnicki%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShalom%2BKalnicki%2B) Madhur Garg 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Madhur%2BGarg%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Garg%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMadhur%2BGarg%2B) Rafi Kabarriti 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rafi%2BKabarriti%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kabarriti%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARafi%2BKabarriti%2B) * For correspondence: rkabarri@montefiore.org * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1303965/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1303965/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1303965/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1303965/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1303965/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Importance: Recurrence rates in head and neck squamous cell carcinoma (HNSCC) remain high, yet current post-treatment surveillance relies primarily on clinical examination and imaging with known limitations. Circulating tumor DNA (ctDNA) has shown promise for recurrence detection in HPV-positive HNSCC, but less is known about its role in non-virally associated disease. Objective: To evaluate the diagnostic performance of a methylation-based ctDNA assay for detecting recurrence during post-treatment surveillance of non-virally associated HNSCC and to assess its prognostic association with survival outcomes. Design, Setting, and Participants: This retrospective single-institution cohort study included patients with non-metastatic non-virally associated HNSCC who underwent definitive therapy and had at least one Guardant360 ctDNA test during post-treatment surveillance between January 2024 and October 2025. Guardant360 identifies tumor-specific DNA methylation patterns via next-generation sequencing of plasma cell-free DNA. A positive result was defined by a methylation signal of 0.05% or greater. Main Outcomes and Measures: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results: Fifty patients were included; most had larynx (38%) or oral cavity (36%) primaries, AJCC stage IVA-IVB disease (72%), T3-T4 tumors (69%), and N2-N3 nodal classification (48%). Treatment was chemoradiation (54%) or surgery (46%). At a median follow-up of 18.0 months, 13 patients recurred, and 12 had positive ctDNA results. Sensitivity, specificity, PPV, and NPV were 76.9%, 94.6%, 83.3%, and 92.1%, respectively (AUC, .858; 95% CI, .733-.982). Positive ctDNA was associated with worse PFS (1-year: 25.0% vs 96.4%; P The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.17.26363296v1 "Genetic analyses of blood pressure traits in 140,000 admixed adults from Mexico City") Posted September 20, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/20/2026.09.17.26363361.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/20/2026.09.17.26363361.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer Danielle Tomer, Patrik Brodin, Nikhil Malik, Sadiya Mayat, Christian Velten, Byung-Han Rhieu, Enrico Castellucci, Bradley Schiff, Vikas Mehta, Richard Smith, Shalom Kalnicki, Madhur Garg, Rafi Kabarriti medRxiv 2026.09.17.26363361; doi: https://doi.org/10.64898/2026.09.17.26363361 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.17.26363361v1%26text%3DMethylation-Based%2520ctDNA%2520for%2520Post-Treatment%2520Surveillance%2520of%2520Non-Viral%2520Head%2520and%2520Neck%2520Cancer "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.17.26363361v1%26t%3DMethylation-Based%2520ctDNA%2520for%2520Post-Treatment%2520Surveillance%2520of%2520Non-Viral%2520Head%2520and%2520Neck%2520Cancer "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.17.26363361v1%26title%3DMethylation-Based%2520ctDNA%2520for%2520Post-Treatment%2520Surveillance%2520of%2520Non-Viral%2520Head%2520and%2520Neck%2520Cancer%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.17.26363361v1%26title%3DMethylation-Based%2520ctDNA%2520for%2520Post-Treatment%2520Surveillance%2520of%2520Non-Viral%2520Head%2520and%2520Neck%2520Cancer "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.17.26363361) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.17.26363361v1&count=horizontal&via=&text=Methylation-Based%20ctDNA%20for%20Post-Treatment%20Surveillance%20of%20Non-Viral%20Head%20and%20Neck%20Cancer&counturl=www.medrxiv.org/content/10.64898/2026.09.17.26363361v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (619) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (903) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (334) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4828) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (479) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (419) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (651) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1633) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15974) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (33) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1206) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7066) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (734) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1067) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5060) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1438) * [Health Systems and Quali
## Related Clinical Research

- [Zero-shot LLMs Outperform Rule-based and NER Methods for Colorectal Cancer Symptom Extraction](https://medichelpline.com/clinical-feed/medrxiv-22-leveraging-large-language-models-for-colorectal-cancer-symptom-extraction-from.md)
- [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md)
- [Sudan civil war damages hospitals, forcing cancer patients into dangerous journeys](https://medichelpline.com/clinical-feed/stat-news-2-in-sudan-attacks-on-hospitals-force-patients-to-make-dangerous-journeys.md)
- [Educating Patients on ‘Asian Glow’ and Alcohol Risks in East Asian Populations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-doctors-should-educate-patients-about-asian-glow-and-drinking-risks.md)
- [Autologous DC-CIK Cell Therapy Combined with Multidisciplinary Care in Advanced Pancreatic Cancer:](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-multidisciplinary-treatment-incorporating-autologous-dc-cik-cell-therapy.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.